News Releases

News Releases

Date Title and Summary Additional Formats
Toggle Summary Clementia Advances Natural History Study of Patients with Fibrodysplasia Ossificans Progressiva
Study Now Enrolling Patients Ages Two through 65 Years Old MONTREAL, CANADA, May 28, 2015  –  Clementia Pharmaceuticals Inc.  today announced that it has commenced enrollment in the second part (Part B) of its natural history study in patientswith fibrodysplasia ossificans
View HTML
Toggle Summary Clementia Advances Phase 2 Clinical Trial of Palovarotene in Fibrodysplasia Ossificans Progressiva Based on Recommendations from Data Monitoring Committee (DMC)
MONTREAL, CANADA, APRIL 2, 2015  –  Clementia Pharmaceuticals Inc.  announced today that the Data Monitoring Committee (DMC) for the company’s Phase 2 adaptive‐design, dose‐ranging study of palovarotene for fibrodysplasia ossificans progressiva (FOP) has completed a planned review of
View HTML
Toggle Summary Clementia Announces Closing of Over-Allotment Option in its Initial Public Offering
MONTREAL , Aug. 21, 2017 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (NASDAQ:CMTA) (the “Company” or “Clementia”), a clinical stage biopharmaceutical company, today announced that the underwriters of its previously announced initial public offering exercised their option to purchase an
View HTML
Toggle Summary Clementia Announces Completion of Enrollment in Phase 3 MOVE Trial for FOP
Enrollment Completed Four Months Ahead of Schedule; Two Interim Data Analyses On Track for 2019 MONTREAL , Aug. 16, 2018 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (NASDAQ: CMTA), a clinical-stage company innovating treatments for individuals with ultra-rare bone disorders and other
View HTML
Toggle Summary Clementia Announces Data Presentations at Upcoming Medical Conferences in September
MONTREAL , Aug. 31, 2017 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (NASDAQ:CMTA), a clinical stage biopharmaceutical company, today announced upcoming data presentations highlighting our palovarotene development efforts at the 2017 American Society for Bone and Mineral Research (ASBMR)
View HTML
Toggle Summary Clementia Announces Date of Corporate Update Conference Call
MONTREAL , Dec. 05, 2017 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (NASDAQ:CMTA), a clinical-stage biopharmaceutical company, today announced that management will host a conference call and webcast at 8:30 a.m. ET on Tuesday, Dec. 12, 2017 , to provide a corporate update and discuss recent
View HTML
Toggle Summary Clementia Announces Last Patient Enrolled in Phase 2 trial of Palovarotene in Patients with Fibrodysplasia Ossificans Progressiva
Joins Global Rare Disease Community in Recognizing Rare Disease Day 2016 MONTREAL, CANADA, February, 29, 2016  – Clementia Pharmaceuticals Inc. today announced that the 40th and last study participant has enrolled into its Phase 2 clinical trial that is investigating palovarotene for the
View HTML
Toggle Summary Clementia Announces Presentation at the J.P. Morgan 36th Annual Healthcare Conference
MONTREAL , Jan. 03, 2018 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (NASDAQ:CMTA), a clinical-stage biopharmaceutical company innovating new treatments for people with ultra-rare bone disorders and other diseases, today announced that Clarissa Desjardins , Ph.D., chief executive officer and
View HTML
Toggle Summary Clementia Announces Pricing of Initial Public Offering
MONTREAL , Aug. 2, 2017 /PRNewswire/ --  Clementia Pharmaceuticals Inc. (NASDAQ: CMTA) (the "Company" or "Clementia"), a clinical stage biopharmaceutical company, today announced the pricing of its initial public offering of 8,000,000 common shares at an initial public offering price of $15 .00 per
View HTML
Toggle Summary Clementia Announces Top-line Results from Phase 2 Trial of Palovarotene for Treatment of Patients with Fibrodysplasia Ossificans Progressiva
MONTREAL, CANADA, October, 14, 2016  – Clementia Pharmaceuticals Inc. today announced top-line results from its Phase 2 clinical trial investigating palovarotene for the treatment of fibrodysplasia ossificans progressiva (FOP). FOP is an extremely rare, serious disease in which an accumulation
View HTML